These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23398379)

  • 1. Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications.
    Contoreggi C; Lee MR; Chrousos G
    Ann N Y Acad Sci; 2013 Apr; 1282():107-18. PubMed ID: 23398379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don't stress about CRF: assessing the translational failures of CRF
    Spierling SR; Zorrilla EP
    Psychopharmacology (Berl); 2017 May; 234(9-10):1467-1481. PubMed ID: 28265716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders.
    Contoreggi C; Rice KC; Chrousos G
    Neuroendocrinology; 2004; 80(2):111-23. PubMed ID: 15523186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRH signaling. Molecular specificity for drug targeting in the CNS.
    Refojo D; Holsboer F
    Ann N Y Acad Sci; 2009 Oct; 1179():106-19. PubMed ID: 19906235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting closer to affective disorders: the role of CRH receptor systems.
    Müller MB; Wurst W
    Trends Mol Med; 2004 Aug; 10(8):409-15. PubMed ID: 15310462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-life stress-induced anxiety-related behavior in adult mice partially requires forebrain corticotropin-releasing hormone receptor 1.
    Wang XD; Labermaier C; Holsboer F; Wurst W; Deussing JM; Müller MB; Schmidt MV
    Eur J Neurosci; 2012 Aug; 36(3):2360-7. PubMed ID: 22672268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential uses of corticotropin-releasing hormone antagonists.
    Zoumakis E; Rice KC; Gold PW; Chrousos GP
    Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of both type-1 and type-2 corticotropin releasing factor receptors in stress-induced relapse to cocaine seeking behaviour.
    Gysling K
    Biochem Pharmacol; 2012 Jan; 83(1):1-5. PubMed ID: 21843515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebroventricular administration of corticotrophin-releasing hormone receptor antagonists produces different effects on hypothalamic pituitary adrenal responses to novel restraint depending on the stress history of the animal.
    Vining C; Iyer V; Bhatnagar S
    J Neuroendocrinol; 2007 Mar; 19(3):198-207. PubMed ID: 17280593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress.
    Müller MB; Zimmermann S; Sillaber I; Hagemeyer TP; Deussing JM; Timpl P; Kormann MS; Droste SK; Kühn R; Reul JM; Holsboer F; Wurst W
    Nat Neurosci; 2003 Oct; 6(10):1100-7. PubMed ID: 12973355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticotropin-releasing hormone modulators and depression.
    Holsboer F
    Curr Opin Investig Drugs; 2003 Jan; 4(1):46-50. PubMed ID: 12625028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a benzodiazepine receptor agonist and corticotropin-releasing hormone receptor antagonists on long-term foot-shock-induced increase in defensive withdrawal behavior.
    Bruijnzeel AW; Stam R; Wiegant VM
    Psychopharmacology (Berl); 2001 Nov; 158(2):132-9. PubMed ID: 11702086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticotropin releasing factor: a key role in the neurobiology of addiction.
    Zorrilla EP; Logrip ML; Koob GF
    Front Neuroendocrinol; 2014 Apr; 35(2):234-44. PubMed ID: 24456850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in corticotropin-releasing factor-1 antagonist development.
    Zorrilla EP; Koob GF
    Drug Discov Today; 2010 May; 15(9-10):371-83. PubMed ID: 20206287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats.
    Raone A; Cassanelli A; Scheggi S; Rauggi R; Danielli B; De Montis MG
    Neuroscience; 2007 Jun; 146(4):1734-42. PubMed ID: 17481824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.
    Gilligan PJ; Li YW
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):487-97. PubMed ID: 15338958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells.
    Keita AV; Söderholm JD; Ericson AC
    Neurogastroenterol Motil; 2010 Jul; 22(7):770-8, e221-2. PubMed ID: 20149111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior.
    Lu A; Steiner MA; Whittle N; Vogl AM; Walser SM; Ableitner M; Refojo D; Ekker M; Rubenstein JL; Stalla GK; Singewald N; Holsboer F; Wotjak CT; Wurst W; Deussing JM
    Mol Psychiatry; 2008 Nov; 13(11):1028-42. PubMed ID: 18475271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.